Brand Name | Status | Last Update |
---|---|---|
locametz | New Drug Application | 2024-07-09 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Prostatic neoplasms | D011471 | — | C61 | 3 | 4 | 3 | — | — | 7 |
Recurrence | D012008 | — | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Castration-resistant prostatic neoplasms | D064129 | — | — | — | 1 | — | — | — | 1 |
Adenocarcinoma | D000230 | — | — | — | 1 | — | — | — | 1 |
Drug common name | Gozetotide alf-18 |
INN | — |
Description | Locametz (gozetotide alf-18) is a small molecule pharmaceutical. Gozetotide alf-18 was first approved as Locametz on 2022-12-09. It has been approved in Europe to treat radionuclide imaging. |
Classification | Small molecule |
Drug class | peptides |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | O=C([O-])CN(CCN(CC(=O)[O-])Cc1cc(CCC(=O)NCCCCCC(=O)NCCCC[C@H](NC(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)O)ccc1O)Cc1cc(CCC(=O)O)ccc1O.[18F-].[Al+3] |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL4650355 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | — |